Open AccessSequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment
Author(s) -
Haiyan Xu,
Di Ma,
Yang Gao,
Junling Li,
Xuezhi Hao,
Puyuan Xing,
Lu Yang,
Fei Xu,
Yan Wang
Publication year - 2019
Publication title -
chinese journal of cancer research/chinese journal of cancer research
Language(s) - English
Resource type - Journals
eISSN - 1993-0631
pISSN - 1000-9604
DOI - 10.21147/j.issn.1000-9604.2019.02.09
Subject(s) - crizotinib , medicine , anaplastic lymphoma kinase , lung cancer , oncology , chemotherapy , progression free survival , tumor progression , alk inhibitor , gastroenterology , cancer , malignant pleural effusion
Crizotinib is recommended as the first-line therapy for advanced anaplastic lymphoma kinase ( ALK )-positive non-small-cell lung cancer (NSCLC). Despite its initial efficacy, patients ultimately acquire resistance to crizotinib within 1 year. In such patients, the optimal sequential therapy after crizotinib treatment remains unknown. This study explored which sequential therapy option confers the greatest benefit.